{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:41:17Z","timestamp":1783496477453,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jpba.2025.116876","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:21:41Z","timestamp":1744165301000},"page":"116876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Stability of the antibiotic ceftaroline fosamil with focus on degradation products and decomposition pathways \u2013 Integrative analysis by LC-DAD, ESI-QTOF and in silico prediction"],"prefix":"10.1016","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0369-8922","authenticated-orcid":false,"given":"Marianna Coelho","family":"Mendes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian Fanfa","family":"Machioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Franco","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Sebastian Loureiro","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.116876_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/antibiotics9020065","article-title":"Strategies to combat multidrug-resistant and persistent infectious diseases","volume":"9","author":"Pacios","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.jpba.2025.116876_bib2","doi-asserted-by":"crossref","unstructured":"U. Theuretzbacher, S. Gottwalt, P. Beyer, M. Butler, L. Czaplewski, C. Lienhardt, L. Moja, M. Paul, S. Paulin, J.H. Rex, L.L. Silver, M. Spigelman, G.E. Thwaites, J.P. Paccaud, S. Harbath, Analysis of the clinical antibacterial and antituberculosis pipeline. Lancet Infect Dis 19. e40-e50. DOI: 10.1016\/S1473-3099(18)30513-9;","DOI":"10.1016\/S1473-3099(18)30513-9"},{"key":"10.1016\/j.jpba.2025.116876_bib3","unstructured":"PFIZER pack insert\u2019s Zinforo\u00ae (Ceftaroline Fosamil). https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=\u200912787, 2022 (accessed 04 Feb 2024);"},{"key":"10.1016\/j.jpba.2025.116876_bib4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cpdd.907","article-title":"Pharmacokinetic and pharmacodynamic target attainment in adult and pediatric patients following administration of ceftaroline fosamil as a 5-minute infusion","volume":"10","author":"Riccobene","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jpba.2025.116876_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jpba.2017.07.060","article-title":"S. Tyski, Identification and determination of related substances of ceftaroline fosamil in medicinal product by high performance liquid chromatography with diode array detection and tandem mass spectrometry","author":"Karpiuk","year":"2017","journal-title":"J. Pharm. Biomed. Anal. 145"},{"key":"10.1016\/j.jpba.2025.116876_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/10826076.2023.2216750","article-title":"Simultaneous monitoring of ceftaroline fosamil and its active form ceftaroline during stability study of commercial sample\u2014a new stability-indicating HPLC method, drug decomposition in clinical use conditions and degradation products by LC-MS","volume":"46","author":"Moretto","year":"2023","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jpba.2025.116876_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e16564","article-title":"Development and validation of an LC-MS\/MS method to quantify ceftaroline in microdialysate samples from plasma and brain: application to a preclinical pharmacokinetic investigation","volume":"9","author":"Helfer","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jpba.2025.116876_bib8","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1136\/ejhpharm-2017-001221","article-title":"Physical and chemical stability of ceftaroline in an elastomeric infusion device","volume":"v. 25","author":"Al Madfai","year":"2018","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.jpba.2025.116876_bib9","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1248\/cpb.56.1406","article-title":"Stability and stabilization studies of TAK-599 (ceftaroline fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825","volume":"v. 56","author":"Ikeda","year":"2008","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.jpba.2025.116876_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.22456\/2527-2616.133273","article-title":"Development and validation of a new analytical method based on UV\u2013visible spectroscopy for quantification of ceftaroline fosamil in powder for injection","volume":"v. 7","author":"Machioli","year":"2023","journal-title":"Drug Anal. Res."},{"key":"10.1016\/j.jpba.2025.116876_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1166\/rase.2013.1039","article-title":"Review on pharmaceutical impurities, stability studies and degradation products: an analytical approach","volume":"2","author":"Alothman","year":"2013","journal-title":"Rev. Adv. Sci. Eng."},{"key":"10.1016\/j.jpba.2025.116876_bib12","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1021\/mp5003976","article-title":"In silico prediction of pharmaceutical degradation pathways: a benchmarking study","volume":"11","author":"Kleinman","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jpba.2025.116876_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/analytica5030030","article-title":"Modified GAPI (MoGAPI) tool and software for the assessment of method greenness: case studies and applications","volume":"v. 5","author":"Mansour","year":"2024","journal-title":"Analytica"},{"key":"10.1016\/j.jpba.2025.116876_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.sampre.2025.100164","article-title":"Click analytical chemistry index as a novel concept and framework, supported with open source software to assess analytical methods","author":"Mansour","year":"2025","journal-title":"Adv. Sample Prep."},{"key":"10.1016\/j.jpba.2025.116876_bib15","article-title":"Green profile tools: current status and future perspectives","volume":"v. 6","author":"Locatelli","year":"2023"},{"key":"10.1016\/j.jpba.2025.116876_bib16","unstructured":"Lhasa Limited Zeneth. Available at: Impurity And DegradantControl https:\/\/www.lhasalimited.org\/solutions\/impurity-and-degradant-control\/ (accessed 04 Feb 2024);"},{"key":"10.1016\/j.jpba.2025.116876_bib17","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1021\/acs.oprd.3c00344","article-title":"In silico prediction of pharmaceutical degradation pathways: a benchmarking study using the software program zeneth","volume":"28","author":"Hemingway","year":"2024","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.jpba.2025.116876_bib18","unstructured":"ICH Harmonised Tripartite Guideline: Impurities in New Drug Substances Q3A(R2), Current Step 4 Version, 2006 (accessed 04 Feb 2024);"},{"key":"10.1016\/j.jpba.2025.116876_bib19","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA): Guide of Stability Studies n\u00ba28\/2019, Version 1, 2029 (accessed 04 Feb 2024);"},{"key":"10.1016\/j.jpba.2025.116876_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.33320\/maced.pharm.bull.2022.68.03.144","article-title":"The effect of critical process parameters in manufacturing (filling process) of dry powders for oral suspensions","volume":"68","author":"Stojanoska","year":"2022","journal-title":"Maced. Pharm. Bull."},{"key":"10.1016\/j.jpba.2025.116876_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.addr.2021.02.016","article-title":"Pharmaceutical protein solids: drying technology, solid-state characterization and stability","volume":"172","author":"Chen","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jpba.2025.116876_bib22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.scitotenv.2013.06.027","article-title":"pH and temperature effects on the hydrolysis of three \u03b2-lactam antibiotics: ampicillin, cefalotin and cefoxitin","volume":"466","author":"Mitchell","year":"2014","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.jpba.2025.116876_bib23","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-015-0281-3","article-title":"A critical review on clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline","volume":"54","author":"Kiang","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2025.116876_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1517\/17425240902824808","article-title":"Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues","volume":"v. 6","author":"Peterson","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jpba.2025.116876_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/ejhpharm-2020-002597","article-title":"Physicochemical stability of carmustine-containing medicinal products after reconstitution and after dilution to ready-to-administer infusion solutions stored refrigerated or at room temperature","volume":"30","author":"Knoll","year":"2023","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.jpba.2025.116876_bib26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/1078155220918025","article-title":"Stability of calcium levofolinate reconstituted in syringes and diluted in NaCl 0.9% and glucose 5% polyolefin\/polyamide infusion bags","volume":"27","author":"Sanogo","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jpba.2025.116876_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135018","article-title":"Thiazole ring-cleavage: versatile products obtained in the course of synthesis of certain sulfonamide derivatives","volume":"1279","author":"Zeidan","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jpba.2025.116876_bib28","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1021\/acs.energyfuels.3c00098","article-title":"Evaluation of molecular fragmentation in polycyclic aromatic hydrocarbons by time-of-flight secondary ion mass spectrometry","volume":"37","author":"Sj\u00f6vall","year":"2023","journal-title":"Energy Fuels"},{"key":"10.1016\/j.jpba.2025.116876_bib29","doi-asserted-by":"crossref","first-page":"25239","DOI":"10.1021\/acsomega.2c02144","article-title":"LC\u2013MS\/MS analysis on infusion bags and filled syringes of decitabine: new data on physicochemical stability of an unstable molecule","volume":"7","author":"Laforgia","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.jpba.2025.116876_bib30","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1002\/anie.200802651","article-title":"Hydrolytic stability of hydrazones and oximes","volume":"47","author":"Kalia","year":"2004","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jpba.2025.116876_bib31","first-page":"163","article-title":"The hydrolysis of lactams, in hydrolysis in drug and prodrug metabolism","author":"Sta","year":"2003","journal-title":"Chem., Biochem., Enzymol."},{"key":"10.1016\/j.jpba.2025.116876_bib32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0028-1083277","article-title":"The thermal amidation of carboxylic acids revisited","author":"Goossen","year":"2009","journal-title":"Synthesis"},{"key":"10.1016\/j.jpba.2025.116876_bib33","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1039\/b403161j","article-title":"Chemoselectivity in reactions of esterification","volume":"2","author":"Nahmany","year":"2004","journal-title":"Org. Biomol. Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525002171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525002171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T20:20:46Z","timestamp":1753388446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708525002171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":33,"alternative-id":["S0731708525002171"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116876","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stability of the antibiotic ceftaroline fosamil with focus on degradation products and decomposition pathways \u2013 Integrative analysis by LC-DAD, ESI-QTOF and in silico prediction","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116876"}}